Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

COVID-19’s origins remain murky one year later

By Brian Buntz | March 10, 2021

SARS-CoV-2 COVID-19 coronavirus

This colorized scanning electron microscope image shows SARS-CoV-2 (round blue objects), the virus that causes COVID-19, emerging from the surface of cells cultured in the lab. [Image courtesy of National Institute of Allergy and Infectious Diseases]

More than a year after COVID-19 became a pandemic, the source of the SARS-CoV-2 virus remains a mystery.

The World Health Organization (WHO) is working on formulating a likely narrative of how the virus first infected humans, but some scientists are pressing for an independent investigation.

An open letter from 26 scientists published by The Wall Street Journal concluded that it is “all but impossible” for the WHO researchers to uncover the virus’s origins given their perceived lack of access to substantive data.

WHO reportedly recently scrapped plans to share interim results from its investigation into the origins of the pandemic, according to WSJ.

Last month, WHO released conflicting statements about its conclusions. Peter Ben Embarek, a WHO program manager, stated that the possibility of an accident at the Wuhan Institute of Virology spreading the virus was “extremely unlikely.” But WHO director-general Tedros Adhanom emphasized, “that all hypotheses remain open and require further study.”

To rule out the lab-leak theory, Embarek points to the lack of reports or publications on the SARS-CoV-2 virus before its emergence in late 2019. “Nowhere previously was this particular virus researched or identified or known,” Embarek said.

The WHO team that visited Wuhan reported finding no evidence of viral samples similar to SARS-CoV-2 in a laboratory there.

Chinese officials have discounted the lab-leak scenario as politically motivated.

The Trump administration entertained the possibility that the SARS-CoV-2 virus emerged from the lab in Wuhan. In the waning days of the administration, the U.S. Department of State released a “Fact Sheet” citing intelligence that pointed to the possibility of accidental infections in the Wuhan Institute of Virology.

While the Fact Sheet didn’t disclose its sources, Chinese researchers indeed had a history of conducting “gain-of-function” research on virtual strains in which researchers attempt to boost their pathogenicity or transmissibility. So did American researchers, but the U.S. issued a moratorium on the practice in 2014.

According to an opinion piece in The Washington Post, the Biden administration has not entirely dismissed the possibility of the lab-leak scenario.

In any event, the NIH had funded research on bat coronaviruses at the Wuhan Institute of Virology, but the U.S. canceled that funding was in April 2020.

Scientists believe that bats were the original host of a predecessor virus to SARS-CoV-2, but the bats that are the likely source of both SARS and SARS-CoV-2 are in Yunnan province, roughly 1,000 miles away.

To explain how the virus first appeared in Wuhan, Chinese officials have entertained the possibility that the frozen meat — perhaps wild meat — was the likely infection source. Pangolins have been floated as a possible intermediary host. The palm civet, ferret badgers and rabbits are other possible contenders.

Many scientists have discounted the likelihood of a lab accident seeding the virus in humans while entertaining the possibility of the SARS-CoV-2 virus jumping directly from an animal to humans or infecting an intermediary animal before infecting humans.


Filed Under: Infectious Disease
Tagged With: coronavirus, covid-19
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Close-up medical syringe with a vaccine.
Six leading medical organizations sue RFK Jr. over vaccine recommendations
RFK’s new ACIP changed longstanding vaccine recommendations
Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE